Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · IEX Real-Time Price · USD
1.840
-0.060 (-3.16%)
At close: Apr 23, 2024, 4:00 PM
1.860
+0.020 (1.09%)
After-hours: Apr 23, 2024, 4:12 PM EDT
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 89 |
| CEO | David J. Lennon Ph.D. |
Contact Details
Address: 17383 Sunset Avenue, Suite A250 Pacific Palisades, California 90272 United States | |
| Phone | 424-473-8055 |
| Website | aadibio.com |
Stock Details
| Ticker Symbol | AADI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001422142 |
| CUSIP Number | 00032Q104 |
| ISIN Number | US00032Q1040 |
| Employer ID | 61-1547850 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Neil P. Desai Ph.D. | Founder, Secretary and Executive Chairman |
| Dr. Loretta M. Itri F.A.C.P., M.D. | Chief Medical Officer |
| David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
| Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
| Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
| Raymond G. Steitz | Senior Vice President of Human Resources and Chief Human Resources Officer |
| Bryan Ball | Chief Quality Officer and Senior Vice President of Manufacturing Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | 8-K | Current Report |
| Mar 13, 2024 | 10-K | Annual Report |
| Mar 13, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 144 | Filing |
| Feb 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 14, 2023 | 8-K | Current Report |
| Dec 1, 2023 | 144 | Filing |
| Nov 8, 2023 | 10-Q | Quarterly Report |
| Nov 8, 2023 | 8-K/A | [Amend] Current report |